Page 8 - Pharma Industry

Over 8.5K MSME pharma units get 1-yr breather to adopt Schedule M standards

Mohfw notifies extension till December 31 for companies under Rs 250 cr turnover

Amazon Pharmacy expands medicine access from Andaman to Arunachal Pradesh

Using Amazon's nationwide logistics network, customers can now access a wide range of medicines, with same-day delivery available in 23 cities, including top metros and Tier-II cities

Pharma industry's success relies on innovation, else it will extinct: Goyal

Commerce and Industry Minister Piyush Goyal on Saturday emphasised on the crucial role of innovation in driving the growth of the Indian pharmaceutical industry and warned that without innovation, the industry will be "finished". He also expressed concern that the industry often relies on government incentives to conduct research and development in the sector. "Sadly, our country's mindset has become so weak that for everything we are looking up to the government... we think that only after getting a tax incentive then only we will do research. This is the industry where innovation determines success, whoever will not innovate will be finished," he said, while addressing members of the drug making firms in Mumbai. He also cautioned that if the industry will not innovate, its future is worrisome. The industry will have to keep pace with the changing lifestyle patterns besides demands and needs of the society and patents, Goyal said. He called upon the industry to come forward with

Gland Pharma Q3 result: Net profit rises 7% to Rs 205 cr as expenses drop

Rivals Sun Pharma and Cipla beat third-quarter profit estimates, while Dr Reddy's missed expectations. All three drugmakers saw muted growth in the North American market, including the US

Sun Pharma Q3FY25 results: Net profit soars 15%, revenue up 10.5%

Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent. Both profit and revenue were in line with Bloomberg estimates

Commerce Ministry withdraws 'track and trace' rule for pharma exports

The Commerce Ministry on Friday said it has withdrawn the provisions related to the track and trace system for pharmaceutical exports under the foreign trade policy. The implementation of the authentication system for drug formulations being exported will be undertaken by the Ministry of Health and Family Welfare in line with the provisions under Drug Rules 1945, according to a public notice of the Directorate General of Foreign Trade (DGFT). "The DGFT has decided to streamline export regulations by aligning with the evolving regulatory framework of the Ministry of Health & Family Welfare. Accordingly, the provisions related to the track and trace system for pharmaceutical exports under the Foreign Trade Policy are being withdrawn," the ministry said. The system, introduced on January 10, 2011, mandated barcoding at various packaging levels. While tertiary and secondary packaging requirements were successfully implemented in 2011 and 2013, primary-level barcoding and parent-child .

CDMO revenues to touch $1.2 bn by FY30: Piramal Pharma chairperson

Says that their growth is led by innovation related work

Doctors may face suspension in NMC probe over pharma-sponsored trips

This was in violation of the UCPMP rules, which regulate interactions between pharmaceutical companies and HCPs and prohibit foreign trips, gifts, and inducements as unethical marketing practices

Granules India Q3FY25 results: Net profit drops 6% to Rs 118 crore

Drug firm Granules India on Friday said its consolidated profit after tax declined 6 per cent year on year to Rs 118 crore for the third quarter ended December 31, 2024. The company reported a profit after tax of Rs 126 crore in the October-December quarter of the last fiscal. Revenue from operations declined to Rs 1,138 crore in the third quarter as against Rs 1,156 crore in the year-ago period, the Hyderabad-based said in a regulatory filing. "We continue to sustain our profitable growth in the finished dosages segment, driven by our North America business. We are enhancing quality and compliance through systemic improvements across our operations, including Gagillapur," Granules India Chairman & Managing Director Krishna Prasad Chigurupati said. The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations. Subsequently, the production resumed in October in a staggered manner, it ...

Granules India focused on getting FDA nod for drug from Gagillapur by FY26

It had voluntarily paused production in September

The India story: The journey to becoming the 'pharmacy of the world'

Critical tweaks in laws, spirit of enterprise and the pandemic brought about this transition. Tech and innovation will now define the industry's future

Senores Pharma IPO sees 13.88 times subscription on day two of bidding

Senores Pharmaceuticals' initial public offering garnered 13.88 times subscription on Monday, the day two of bidding. The Rs 582-crore initial share sale got bids for 11,84,54,740 shares, as against 85,34,681 shares on offer, as per NSE data. The portion for Retail Individual Investors (RIIs) received 38.34 times subscription, while the non-institutional investors segment got subscribed 24.48 times. Qualified Institutional Buyers (QIBs) part received 35 per cent subscription. Senores Pharmaceuticals Ltd on Thursday said it has secured nearly Rs 261 crore from anchor investors. The IPO will conclude on December 24. The IPO has a price range of Rs 372-391 per share. The Ahmedabad-based company's IPO is a combination of fresh issuance of shares worth Rs 500 crore and an Offer-for-Sale (OFS) of up to 21 lakh shares valued Rs 82.11 crore, by promoters and other selling shareholders, at the upper-end of the price band. Proceeds from the fresh issue will be utilised for setting up a ...

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Pharma industry expo to be held in Greater Noida from November 26-28

The 17th edition of the CPHI and PMEC expo showcasing the pharmaceutical industry's modernisation, innovation and sustainability will be held from November 26 to 28 in Greater Noida. The expo will this year offer a pivotal marketplace for over 2,000 exhibitors to engage with anticipated participation from countries, including the US, UAE, South Korea, Japan, Egypt, Vietnam, the Philippines, Malaysia, Italy, Sri Lanka, Bangladesh, Nepal, Iran, and the United Kingdom. The expo will showcase over 10,000 products, offering a unique space for collaboration and innovation in the pharma industry, said a release from the organiser Informa Markets in India. The noteworthy exhibitors include Dr Reddy's Laboratories Ltd, Biocon Ltd, Glenmark Lifesciences Ltd, Morepen Laboratories Ltd, Hetero Labs Limited, Lupin Ltd, Signet Excipients Pvt. Ltd, MSN Laboratories Pvt. Ltd, Sekhmet Pharmaventures Pvt. Ltd, Tirupati Lifesciences Pvt. Ltd, Merck Life Science Pvt. Ltd. and many others, the statement

AstraZeneca Pharma India results: Q2FY25 net profit falls 27% to Rs 38 cr

AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second quarter ended on September 30, 2024. The drug firm reported a net profit of Rs 52 crore in the July-September quarter of last fiscal. Revenue from operations stood at Rs 408 crore for the period under review compared with Rs 311 crore in the year-ago period, the firm said in a regulatory filing. Shares of the company ended 3.74 per cent lower at Rs 7,133.10 apiece on the BSE.

Indian pharmaceutical market registers over 6% growth in October 2024

The value growth comes at a time when the IPM has registered a negative volume growth of 1.8 per cent

Novo Nordisk expects high demand for obesity drugs in India: Country head

The company is still 'evaluating' the price of the drug, but is confident that the price-sensitive Indian population will be able to afford it, Novo's India Managing Director Vikrant Shrotriya said

Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics CEO & MD

Shreehas Tambe, MD & CEO, Biocon Biologics talks about refinancing, upcoming launches, and future roadmap, in a virtual interaction

Cipla Q2 results: Net profit rises 15% to Rs 1,303 crore, revenue up 5.6%

Cipla eyes growth in the Indian and US markets with upcoming launches

Sun Pharma Q2 profit up 28% on strong domestic, emerging mkts performance

The company launched 14 new products in India this quarter